致康胶囊对溃疡性结肠炎患者血清TNF-α、IL-6及CRP的影响

Influence of ZhiKang Capsules on Serum TNF-α, IL-6 and CRP of the Patients with Ulcerative Colitis

目的：观察致康胶囊治疗溃疡性结肠炎的疗效及对患者血清肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）及C反应蛋白（CRP）的影响。方法：将58例患者随机分为观察组和对照组,每组29例。对照组给予常规治疗。观察组在此基础上,给予致康胶囊治疗。结果：总有效率观察组为96.55%,对照组为72.41%,2组比较差异有统计学意义（P〈0.05）。治疗后血清TNF-α、IL-6、CRP观察组分别为（23.5±2.7）ng/L、（31.6±1.3）ng/L、（3.2±0.9）mg/L,对照组分别为（47.2±5.8）ng/L、（47.3±4.5）ng/L、（5.1±1.2）mg/L,2组比较差异有统计学意义（P〈0.05）。治疗后,纤维蛋白原（FIB）、血小板计数（PLT）、血小板平均体积（MPV）观察组分别为（3.0±0.8）g/L、（209.7±45.3）×10~9/L、（9.0±1.4）f L,对照组分别为（4.1±0.3）g/L、（236.1±39.5）×10~9/L、（12.1±1.2）f L,2组比较差异均有统计学意义（P〈0.05）。治疗后,血小板最大聚集率（PAGMax）指标观察组高于对照组（P〈0.05）。治疗后,白蛋白水平观察组为（31.4±2.1）g/L,对照组为（28.1±2.0）g/L,2组比较差异有统计学意义（P〈0.05）。治疗后,生活质量评分观察组为（82.3±9.2）分,对照组为（76.4±7.8）分,2组比较差异有统计学意义（P〈0.05）。结论：致康胶囊治疗溃疡性结肠炎疗效显著,能够降低患者血清TNF-α、IL-6及CRP水平,减轻炎症反应程度,改善患者血凝状态,并有效提高患者生活质量。

Objective： To observe clinical effects of ZhiKang capsules in treating ulcerative colitis（UC） and its influence of Zhi Kang capsules on TNF-α, IL-6 and CRP of the patients. Methods： All 58 patients were randomized into the observation group and the control group, 29 cases each group. The control group accepted routine treatment.The observation group took ZhiKang capsules on the basis of routine treatment. Results： Total effective rates of the observation group and the control group were 96.55% and 72.41%, the difference had statistical meaning between both groups（P〈0.05）. After treating, the concentrations of TNF-α, IL-6 and CRP in the observation group were（23.5 ±2.7） ng/L,（31.6 ±1.3） ng/L and（3.2 ±0.9）mg/L, lower than（47.2 ±5.8） ng/L,（47.3 ±4.5）ng/L and（5.1 ±1.2）mg/L, the difference had statistical meaning between both groups（P〈0.05）. After treating, the concentrations of FIB, PLT and MPV in the observation group were（3.0±0.8）g/L,（209.7±45.3）×10~9g/L and（9.0±1.4）f L, lower than（4.1±0.3） g/L,（236.1±39.5）×10~9g/L and（12.1±1.2）f L of the control group, the difference showed statistical meaning（P〈0.05）. After treating, the observation group was higher than the control group in PAGMaxindexes（P〈0.05）.After treating, the levels of albumin in the observation group were（31.4±2.1） g/L, higher than（28.1±2.0） g/L of the control group, the difference presented statistical meaning between both groups（P〈0.05）. After treating, quality of life（QOL） scales in the observation group were（82.3 ±9.2）, higher than（76.4±7.8） of the control group, and the difference showed statistical meaning between both groups（P〈0.05）. Conclusion： ZhiKang capsules are effective in treating UC patients, they could decrease the levels of TNF-α, IL-6 and CRP of the patients, relieve the degrees of inflammation, improve blood coagulation state of the patients and effectively improve QOL of the patients.